Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Analysis of Inotuzumab Ozogamicin (InO) Usage in Adult Patients With Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia (ALL)

NCT05597085 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05597085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05597085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Analysis of Inotuzumab Ozogamicin (InO) Usage in Adult Patients With Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
March 8, 2023
Completion date
July 10, 2023
Enrollment
32 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adult relapsed/refractory b cell acute lymphoblastic leukemia